Betaferon® Regulatory Post-Marketing Surveillance

Bayer

Status: Completed

Conditions: Multiple Sclerosis; Clinically Isolated System

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01414816

14839

BF0814KR (Other Identifier)

Details and patient eligibility

About

To identify problems/questions about following items in the clinical practice using Betaferon

1. Unknown adverse event (especially serious adverse event)
2. Identification of adverse event occurred in the real practice
3. Factors that may affect the safety of drug
4. Factors that may affect the effectiveness of the drug

Enrollment: 355 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosis of MS or CIS and decision taken by the physician to prescribe Betaferon
• Patients who have not participated in Betaferon regulatory Post Marketing Surveillance before.

Exclusion criteria

• Exclusion criteria must be read in conjunction with local product information

Trial design

355 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)